XII . 
References 
1. Morton DL, Wong JH, Kirkwood JM et al : Malignant melanoma. In: Cancer 
Medicine, p. 1793, Philadelphia: Lea & Febiger, 1993. 
2. Rosenberg SA: Adoptive immunotherapy of cancer using lymphokine 
activated killer cells and recombinant interleukin-2. In: Important 
Advances in Oncology, p. 55, Philadelphia: JB Lippincott Co, 1986. 
3. Rosenberg SA: Karnofsky Memorial Lecture: The immunotherapy and gene 
therapy of cancer. J Clin Oncol 10:180-199, 1992. 
4. Dutcher JP, Creekmore S, Weiss GR: A phase II study of interleukin-2 
and lymphokine-activated killer cells in patients with metastatic 
malignant melanoma. J Clin Oncol 7:477-485, 1989. 
5. Parkinson DR, Abrams JS, Wiernik PH et al: Interleukin-2 therapy in 
patients with metastatic malignant melanoma: A phase II study. J Clin 
Oncol 8:1650-1656, 1990. 
6. McCabe MS, Stablein D, Hawkins M J : The Modified Group C experience - 
phase III randomized trials of IL-2 vs IL-2/LAK in advanced renal cell 
carcinoma and advanced melanoma. Proc Am Soc Clin Oncol 10:213, 1991. 
7. Rosenberg SA, Lotze MT, Yang JC et al: Prospective randomized trial of 
high-dose interleukin-2 alone or in conjunction with lymphokine- 
activated killer cells for the treatment of patients with advanced 
cancer. J Natl Cancer Inst 85:622-632, 1993. 
8. Rubin JT, Elwood LJ, Rosenberg SA et al : Immunohistochemical correlates 
of response to recombinant Interleukin-2 based immunotherapy in humans. 
Cancer Res 49:7086-7092, 1989. 
9. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive 
immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 
233:1318-1321, 1986. 
10. Aebersold P, Hyatt C, Johnson S et al : Lysis of autologous melanoma 
cells by tumor-infiltrating lymphocytes: association with clinical 
response. J Natl Cancer Inst 83:932-937, 1991. 
11. Marincola FM, Venzon D, White D et al: HLA association with response 
and toxicity in melanoma patients treated with interleukin 2-based 
immunotherapy. Cancer Res 52:6561-6566, 1992. 
12. Morton DL , Foshag LJ, Hoon DS et al: Prolongation of survival in 
metastatic melanoma after active specific immunotherapy with a new 
polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992. 
13. Horn SS, Topalian SL, Simonis T et al: Common expression of melanoma 
tumor-associated antigens recognized by human tumor infiltrating 
lymphocytes: analysis by human lymphocyte antigen restriction. J 
Immunotherapy 10:153-164, 1991. 
Recombinant DNA Research, Volume 18 
[739] 
